Clinical Trials Browser

Completed × INDUSTRY × relatlimab × Clear all

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01968109 2026-01-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Tumor-Agnostic

Neoplasms by Site

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Completed

100 enrolled

Dermatologic

Melanoma

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03459222 2025-04-02

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

229 enrolled

Advanced Cancer

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

35 enrolled

Tumor-Agnostic

Neoplasms

NCT03310619 2024-04-04

PLATFORM

Phase 1/2 Completed

62 enrolled 41 charts

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05498480 2024-02-20

RELATIVITY-111

Phase 1 Completed

6 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT02996110 2022-12-19

FRACTION-RCC

Phase 2 Completed

182 enrolled 23 charts

Advanced Cancer

Clinical Trials

RELATIVITY-069

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

CheckMate142

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

PLATFORM

RELATIVITY-111

FRACTION-GC

FRACTION-RCC